The Cromer blood group system: a review

Area of Science:

• Immunology
• Hematology
• Genetics

Background:

• The Cromer blood group system antigens are located on decay-accelerating factor (DAF), a protein in the regulators of complement activation family.
• This system comprises 12 high-prevalence and three low-prevalence antigens, with known molecular underpinnings.
• Most antigens result from single nucleotide changes in the DAF gene, localized to specific complement control protein (CCP) domains.

Purpose of the Study:

• To review the characteristics of the Cromer blood group system.
• To discuss the molecular basis and clinical significance of Cromer antigens and associated antibodies.

Main Methods:

• Literature review of studies on Cromer blood group system antigens and decay-accelerating factor (DAF).
• Analysis of the genetic basis and protein localization of Cromer antigens.
• Examination of clinical implications, including transfusion reactions and hemolytic disease of the newborn (HDN).

Main Results:

• Individuals with the Cromer null phenotype (Inab) lack DAF but show no increased hemolysis susceptibility.
• Antibodies to Cromer antigens are infrequent but can lead to accelerated destruction of transfused red blood cells (RBCs).
• No risk of HDN is associated with Cromer system antibodies due to abundant fetally derived DAF in the placenta.

Conclusions:

• The Cromer blood group system, based on DAF, has well-defined antigens with specific genetic origins.
• While anti-Cromer antibodies pose a transfusion risk, they do not cause HDN, highlighting the protective role of placental DAF.